Compare AIOT & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIOT | CRBP |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.6M | 168.3M |
| IPO Year | 2024 | 2014 |
| Metric | AIOT | CRBP |
|---|---|---|
| Price | $3.01 | $9.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $10.33 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 2.3M | 343.4K |
| Earning Date | 06-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.12 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $443,777,000.00 | $4,822,272.00 |
| Revenue This Year | $24.46 | N/A |
| Revenue Next Year | $9.01 | $116.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 22.42 | ★ 97.62 |
| 52 Week Low | $2.78 | $7.12 |
| 52 Week High | $5.88 | $20.56 |
| Indicator | AIOT | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 57.29 |
| Support Level | $2.86 | $8.30 |
| Resistance Level | $3.39 | $10.74 |
| Average True Range (ATR) | 0.21 | 0.51 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 14.98 | 58.92 |
PowerFleet Inc provides artificial intelligence of things (AIoT) software-as-a-service (SaaS) solutions for the mobile asset industry globally. The company's Unity data highway and AIoT ecosystem ingest data from multiple data sources and deliver actionable insights through a Software-as-a-Service (SaaS) platform, for improving the performance of the mobile asset (such as forklifts, tuggers, trucks, rental cars, etc.), the individual in charge, and the business process. Its offerings include a variety of IoT devices integrated with software solutions for asset tracking, operational monitoring, AI-powered video safety, compliance management, and analytics under brands such as Powerfleet, Pointer, Cellocator, MiX by Powerfleet, and Fleet Complete. The company's key market is North America.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.